The first
FDA-approved
pegfilgrastim biosimilar
FULPHILA® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. FULPHILA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.1
Helps protect your patients at risk of febrile neutropenia
FULPHILA is indicated to decrease the incidence of infection, as manifested by febrile
neutropenia, in
patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated
with a
clinically significant incidence of febrile neutropenia.1
FULPHILA is not indicated for the mobilization of
peripheral blood progenitor cells for hematopoietic stem cell transplantation.
References:
- Fulphila® (pegfilgrastim-jmdb) injection. Prescribing information. 2023. Biocon Biologics Inc. Cambridge, MA.
-
U.S. Food and Drug Administration. Biosimilars. Available at:
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm.
Accessed on: 10 August 2023. - Vogel C, et al. J Clin Oncol. 2005;23:1178-1184.
- Waller, C.F., Ranganna, G.M., Pennella, E.J. et al. Ann Hematol. (2019) 98: 1217.
